Clinical and Endoscopic Response to Anti-Tumor Necrosis Factor-Alpha Antibody Therapy in a Patient With Cronkhite-Canada Syndrome-Reference-Cited by-同舟云学术

Clinical and Endoscopic Response to Anti-Tumor Necrosis Factor-Alpha Antibody Therapy in a Patient With Cronkhite-Canada Syndrome

Published:2023-01 Issue: Volume:11 Page:232470962311794
ISSN:2324-7096
Container-title:Journal of Investigative Medicine High Impact Case Reports
language:en
Short-container-title:Journal of Investigative Medicine High Impact Case Reports

Author:

Salman Roghani Roham¹^ORCID,De Castro Joline¹,Ajumobi Adewale B.¹²

Affiliation:

1. Eisenhower Health, Rancho Mirage, CA, USA

2. University of California, Riverside, USA

Abstract

Cronkhite-Canada syndrome (CCS) is an acquired polyposis syndrome with gastrointestinal and extraintestinal manifestations. Given its rarity and lack of standard treatment, diagnosis and treatment are challenging. Steroid therapy and nutritional support are conventional treatments. There is no consensus on management of steroid-refractory cases. Here, we report the diagnosis and treatment course of a 54-year-old Asian male with CCS, whose initial treatment with prednisone 60 mg a day led to partial response and disease flare up during prednisone tapering. The use of infliximab and azathioprine led to promising remission of his symptoms.

Publisher

SAGE Publications

Subject

Safety Research,Safety, Risk, Reliability and Quality,Epidemiology

Link

http://journals.sagepub.com/doi/pdf/10.1177/23247096231179451

Reference17 articles.

1. Cronkhite-Canada Syndrome Successfully Treated by Corticosteroids before Presenting Typical Ectodermal Symptoms

2. Cronkhite–Canada syndrome six decades on: the many faces of an enigmatic disease

3. The Cronkhite-Canada Syndrome

4. Cronkhite–Canada syndrome showing elevated levels of antinuclear and anticentromere antibody

5. Cronkhite-Canada syndrome polyps infiltrated with IgG4-positive plasma cells